Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
29.08. | Artiva Biotherapeutics GAAP EPS of -$22.00 | 1 | Seeking Alpha | ||
29.08. | Artiva Biotherapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
29.08. | Artiva Biotherapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
29.08. | Artiva Biotherapeutics, Inc.: Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights | 119 | GlobeNewswire (Europe) | Strong balance sheet with successful completion of upsized $179.0 million initial public offering Treatment initiated in the first patient in an investigator-initiated basket trial of AlloNK® exploring... ► Artikel lesen | |
13.08. | Artiva Biotherapeutics' Investigational Scalable Cell Therapies For Autoimmune Disorders, Analyst Initiate With Bullish Pitch | 1 | Benzinga.com | ||
13.08. | Artiva shares recieve Outperform rating from Wedbush | 1 | Investing.com | ||
13.08. | Artiva Biotherapeutics shares get Overweight rating | 1 | Investing.com | ||
13.08. | TD Cowen sees Artiva stock growth potential with unique cell therapy approach | 1 | Investing.com | ||
13.08. | Jefferies bullish on Artiva Biotherapeutics stock, cites promising NK-cell therapy | 1 | Investing.com | ||
23.07. | Hedge Fund and Insider Trading News: Bill Ackman, Ken Griffin, BlueCrest Capital Management, Hudson Bay Capital Management, Brevan Howard, Millennium Management, Artiva Biotherapeutics Inc (ARTV), Best Buy Co Inc (BBY), and More | 3 | Insider Monkey | ||
22.07. | Artiva Biotherapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
22.07. | Artiva Biotherapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
22.07. | RTW Biotech Opp. - Artiva Biotherapeutics prices IPO at $167 million | - | RNS | ||
21.07. | Artiva's IPO Reels In $167M to Bring NK Cell Therapy to Autoimmune Diseases | 1 | MedCity News | ||
19.07. | Artiva Shares Jump 30% After Upsized $167 Million US IPO | 2 | BNN Bloomberg | ||
19.07. | Artiva Biotherapeutics surges on trading debut | 1 | Seeking Alpha | ||
19.07. | Artiva Biotherapeutics IPO opens at $16, priced at $12 | 2 | Investing.com | ||
19.07. | Autoimmune biotech Artiva Biotherapeutics offers more shares, prices IPO below the range at $12 | 2 | Renaissance Capital | ||
19.07. | Artiva upsizes IPO to $167 million as NK cell therapy biotech heads to Nasdaq | 2 | FierceBiotech | ||
19.07. | Artiva Biotherapeutics Prices 13.92M Share IPO at $12/sh | 1 | Investing.com |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 81,45 | +0,37 % | BioNTech Aktie: Neue Daten auf ESMO-Kongress | ||
CUREVAC | 2,488 | +0,89 % | CureVac Aktie: Erneuter Kursrückgang trotz Forschungsfortschritten | ||
AMGEN | 288,80 | -0,10 % | GSK's Asthma Drug Meets Main Goal In Phase 3 Study In Patients With Smoker's Lungs, Prepares Competition With Amgen/AstraZeneca's Drug | ||
NOVAVAX | 10,510 | +0,08 % | Biotech-Favorit im September: Ocugen, Novavax, Clinuvel, Cytodyn | Immer mehr Profis erwarten eine neue Biotech-Hausse und positionieren sich für eine lange Rallye im Sektor. Cleveres Stockpicking ist jetzt entscheidend. Der anlaufende Monat September, ein historisch... ► Artikel lesen | |
BIOGEN | 180,95 | -0,08 % | Biogen-Aktie mit Kursverlusten (179,8723 €) | Im US-amerikanischen Wertpapierhandel notiert das Wertpapier von Biogen zur Stunde ein wenig leichter. Das Papier kostete zuletzt 199,50 US-Dollar. Ein Wertverlust in Höhe von 2,48 US-Dollar müssen... ► Artikel lesen | |
MAINZ BIOMED | 0,303 | +2,72 % | EQS-News: Mainz BioMed N.V.: Partnerschaft mit Liquid Biosciences soll Potenzial der Künstlichen Intelligenz zur Erweiterung und Optimierung der Biomarkerauswahl für PancAlert nutzen | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Sonstiges
Mainz Biomed: Partnerschaft mit Liquid Biosciences soll Potenzial der Künstlichen Intelligenz zur Erweiterung... ► Artikel lesen | |
INTELLIA THERAPEUTICS | 17,810 | +0,11 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based... ► Artikel lesen | |
VIKING THERAPEUTICS | 49,210 | +0,76 % | Billionaires Are Buying Viking Therapeutics Stock Left and Right. Should You Follow Their Lead? | ||
BIOCRYST PHARMACEUTICALS | 7,208 | +0,08 % | BioCryst Pharmaceuticals, Inc.: BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | RESEARCH TRIANGLE PARK, N.C., Sept. 04, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted... ► Artikel lesen | |
CARDIOL THERAPEUTICS | 1,618 | -2,29 % | Startschuss für eine Rally? BioNTech, Pfizer und Bayer genau prüfen, Hammer-News bei Cardiol Therapeutics und Evotec zu erwarten | Trotz aller Unkenrufe: Das Leben geht auch im BioTech-Sektor weiter. Mit einem mittelfristigen Fokus macht es Sinn auf die Management-Qualitäten zu setzen, denn die Kursabschläge fielen teilweise zu... ► Artikel lesen | |
EXELIXIS | 22,760 | +0,35 % | Exelixis stock price target upped by BofA as patent dispute nears resolution | ||
SAREPTA THERAPEUTICS | 116,45 | +0,13 % | Unveiling 26 Analyst Insights On Sarepta Therapeutics | ||
VAXART | 0,814 | +1,94 % | Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SOUTH SAN FRANCISCO, Calif., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the "Company" or "Vaxart") today announced that on August 26, 2024, the Compensation Committee of the Board... ► Artikel lesen | |
PACIFIC BIOSCIENCES OF CALIFORNIA | 1,377 | -3,01 % | PacBio: Revio to Power Research in Male Infertility and Rare Disease at Münster University Hospital | ||
EXACT SCIENCES | 54,97 | +3,17 % | Exact Sciences Announces Second-Quarter 2024 Results | MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the Company generated revenue of $699 million... ► Artikel lesen |